Bimizza
Is It Right for You?
A complete guide to Bimizza — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Bimizza?
Bimizza is the brand name for bimekizumab, a humanised monoclonal IgG1 antibody that selectively inhibits both interleukin-17A (IL-17A) and interleukin-17F (IL-17F) — two cytokines that play pivotal roles in driving the chronic inflammation underlying plaque psoriasis. It is administered as a subcutaneous injection and is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Bimekizumab belongs to the class of biological disease-modifying therapies (biologic DMARDs) and represents an advance over IL-17A-only inhibitors (such as secukinumab and ixekizumab) by also blocking IL-17F, a cytokine that acts synergistically with IL-17A in driving psoriatic inflammation and which may contribute to residual disease activity when IL-17A alone is inhibited.
Bimizza is a prescription-only biological therapy that is initiated and supervised by specialist dermatologists or rheumatologists. Significant pre-treatment screening (including tuberculosis, hepatitis B/C, and other infections) is required before initiation.
What Conditions Is Bimizza Used For?
Moderate to severe plaque psoriasis — in adults who are candidates for systemic therapy and have had an inadequate response to, or who are intolerant of, conventional systemic treatments.
in adults who are candidates for systemic therapy and have had an inadequate response to, or who are intolerant of, conventional systemic treatments (such as methotrexate, ciclosporin, or acitretin)
bimekizumab is in clinical development for psoriatic arthritis; current licensed use is for plaque psoriasis
Unlike topical treatments, bimekizumab modifies the underlying immune dysregulation driving psoriasis. It requires careful pre-treatment screening, infection monitoring, and regular clinical review. It is not a first-line treatment and is prescribed only after conventional systemic therapies have been considered.
How Does Bimizza Work?
Psoriasis is driven by a dysregulated T-cell-mediated immune response in which Th17 lymphocytes and innate immune cells produce excess pro-inflammatory cytokines — particularly IL-17A and IL-17F — that stimulate keratinocyte hyperproliferation and recruitment of neutrophils and other immune cells into the skin, producing the characteristic plaques.
Dual IL-17A and IL-17F inhibition — bimekizumab is a high-affinity monoclonal antibody that simultaneously binds and neutralises both IL-17A and IL-17F with high specificity. By blocking both cytokines, bimekizumab more comprehensively suppresses the Th17-driven inflammatory cascade than inhibitors targeting IL-17A alone. This dual inhibition is associated with very high rates of skin clearance in clinical trials — PASI 90 (90% reduction in Psoriasis Area and Severity Index) rates exceeding 85–90% at week 16.
Bimekizumab does not deplete immune cells and has no direct effect on TNF, IL-12, or IL-23 pathways, distinguishing its mechanism from TNF inhibitors and IL-23 inhibitors.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Bimizza is administered as a subcutaneous injection into the thigh, abdomen, or outer upper arm. Patients may be trained to self-inject following initial administration by a healthcare professional.
Rotate injection sites with each dose to reduce localised injection site reactions.
Remove from the refrigerator 30–45 minutes before use to allow the solution to reach room temperature, which reduces injection discomfort.
Do not inject into areas of active psoriatic plaque, broken skin, bruising, or inflammation.
Maintain up-to-date vaccinations before starting biological therapy — live vaccines are contraindicated during treatment.
Regular monitoring — including assessment for infections (particularly oral candidiasis and inflammatory bowel disease) — is required throughout treatment.
Side Effects of Bimizza
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Oral candidiasis (oral thrush) — one of the most common adverse effects
- Upper respiratory tract infections — nasopharyngitis, pharyngitis
- Injection site reactions — pain, redness, swelling
- Headache
- Fatigue
- Serious infections — including tuberculosis reactivation, invasive fungal infections, and bacterial infections
- Inflammatory bowel disease (IBD) — new onset or exacerbation of Crohn's disease or ulcerative colitis
- Hypersensitivity / anaphylaxis — urticaria, bronchospasm, angioedema following injection
IL-17 plays a critical role in mucosal immunity against Candida and extracellular bacteria. Inhibition of both IL-17A and IL-17F increases susceptibility to infections. Patients must be screened and treated for latent tuberculosis before starting bimekizumab.
Drug Interactions
Always disclose all prescription drugs, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting Bimizza
live attenuated vaccines are contraindicated during bimekizumab treatment due to the risk of disseminated infection from the vaccine organism. All required live vaccines should be completed before starting treatment.
additive immunosuppression increases infection risk; combination use requires careful clinical monitoring.
IL-17 inhibition may alter CYP450 enzyme activity. Plasma levels of drugs metabolised by CYP3A4, CYP2C9, or CYP1A2 should be monitored when initiating or stopping bimekizumab, particularly for narrow therapeutic index drugs such as warfarin or ciclosporin.
Important Warnings
All patients must be screened for latent and active TB before initiating bimekizumab. Latent TB must be treated before biologic therapy begins. Patients who develop signs or symptoms of TB during treatment must stop the drug and seek urgent assessment.
Bimekizumab is contraindicated in patients with active Crohn's disease or ulcerative colitis, and should be used with extreme caution in patients with a history of IBD. New onset or worsening of IBD symptoms during treatment requires prompt evaluation and may necessitate discontinuation.
Oral candidiasis is common; patients should be monitored and treated promptly. Oesophageal candidiasis, whilst less common, requires assessment and treatment. Patients should report white patches, oral soreness, or difficulty swallowing.
Complete all required vaccinations before starting biological therapy. Inactivated vaccines may be given during treatment but may elicit a reduced immunological response. Live vaccines must not be given during treatment or for at least 12 weeks after the last dose.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Bimizza FAQs
Clinical trial data demonstrate that bimekizumab achieves some of the highest rates of complete or near-complete skin clearance (PASI 100 and PASI 90) of any approved biologic for plaque psoriasis, outperforming IL-17A inhibitors (secukinumab, ixekizumab) and IL-12/23 inhibitors (ustekinumab) in head-to-head comparisons in terms of speed and degree of clearance.
IL-17 plays a key role in mucosal immunity against Candida albicans. By inhibiting both IL-17A and IL-17F, bimekizumab reduces this mucosal defence, making oral and oesophageal candidiasis more common than with other biologic classes. Most cases are mild and respond well to standard antifungal treatment.
For minor infections (such as a cold or urinary tract infection), bimekizumab may be continued under clinician guidance. For serious infections, it should be withheld until the infection has fully resolved. Always inform your specialist immediately if you develop fever, signs of infection, or any unusual symptoms.
Bimizza is a long-term maintenance therapy. Clinical trial data show sustained efficacy out to at least two years. Treatment continuation is reviewed regularly by your dermatologist based on response and tolerability.
Many patients are trained to self-inject Bimizza at home after their initial doses administered in clinic. Your specialist team will provide training, written guidance, and ongoing support for self-administration.